Journal of Cancer Research and Practice,
Journal Year:
2024,
Volume and Issue:
11(4), P. 151 - 154
Published: Oct. 1, 2024
Abstract
Soft-tissue
metastasis
from
urothelial
carcinoma
is
a
rare
but
advanced
disease
entity.
We
report
patient
with
muscle-invasive
bladder
cancer
who
experienced
rapid
recurrence
following
radical
surgery
and
adjuvant
platinum-based
chemotherapy.
Despite
further
treatment
taxane-based
chemotherapy
immune
checkpoint
inhibitors,
the
developed
diffuse
soft-tissue
metastases,
including
in
skin,
muscles
of
extraocular
area,
extremities,
trunk.
Salvage
enfortumab
vedotin
(EV)
was
administered
along
local
radiation
therapy
to
orbital
for
better
symptom
control.
Unexpectedly,
metastases
showed
dramatic
response
after
first
cycle
EV.
However,
two
cycles
EV
treatment,
skin
extremity
muscular
progressed,
while
remained
controlled.
Four
months
died
due
systemic
progression
infection.
Biomedicine & Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
176, P. 116783 - 116783
Published: May 25, 2024
During
tumor
development,
the
itself
must
continuously
generate
new
blood
vessels
to
meet
their
growth
needs
while
also
allowing
for
invasion
and
metastasis.
One
of
most
common
features
tumors
is
hypoxia,
which
drives
process
angiogenesis
by
regulating
microenvironment,
thus
adversely
affecting
prognosis
patients.
In
addition,
overcome
unsuitable
environments
growth,
such
as
nutrient
deficiency,
hyperacidity,
immunosuppression,
microenvironment
(TME)
coordinates
in
several
ways
restore
supply
oxygen
nutrients
remove
metabolic
wastes.
A
growing
body
research
suggests
that
hypoxia
interact
through
a
complex
interplay
crosstalk,
inextricably
linked
TME.
Here,
we
review
TME's
positive
contribution
from
an
angiogenesis-centric
perspective
considering
objective
impact
hypoxic
phenotypes
status
limitations
current
angiogenic
therapies.
MedComm,
Journal Year:
2024,
Volume and Issue:
5(9)
Published: Aug. 21, 2024
Head
and
neck
cancer
(HNC)
is
a
highly
aggressive
type
of
tumor
characterized
by
delayed
diagnosis,
recurrence,
metastasis,
relapse,
drug
resistance.
The
occurrence
HNC
were
associated
with
smoking,
alcohol
abuse
(or
both),
human
papillomavirus
infection,
complex
genetic
epigenetic
predisposition.
Currently,
surgery
radiotherapy
are
the
standard
treatments
for
most
patients
early-stage
HNC.
For
recurrent
or
metastatic
(R/M)
HNC,
first-line
treatment
platinum-based
chemotherapy
combined
antiepidermal
growth
factor
receptor
cetuximab,
when
resurgery
radiation
therapy
not
an
option.
However,
curing
remains
challenging,
especially
in
cases
metastasis.
In
this
review,
we
summarize
pathogenesis
including
changes,
abnormal
signaling
pathways,
immune
regulation
mechanisms,
along
all
potential
therapeutic
strategies
such
as
molecular
targeted
therapy,
immunotherapy,
gene
modifications,
combination
therapies.
Recent
preclinical
clinical
studies
that
may
offer
future
research
on
also
discussed.
Additionally,
new
targets
methods,
antibody-drug
conjugates,
photodynamic
radionuclide
mRNA
vaccines,
have
shown
promising
results
trials,
offering
prospects
American Society of Clinical Oncology Educational Book,
Journal Year:
2025,
Volume and Issue:
45(2)
Published: Jan. 1, 2025
Antibody-drug
conjugates
(ADCs)
represent
an
emerging
class
of
therapeutics
across
solid
tumor
oncology
and
are
already
positioned
as
a
cornerstone
therapy
for
patients
with
urothelial
carcinoma
(UC).
In
recent
years,
there
has
been
paradigm
shift
in
the
therapeutic
landscape
frontline
treatment
UC
formerly
relied
on
use
platinum-based
agents
now
evolved
to
include
combination
strategies
ADCs.
These
dramatic
changes
due
part
our
improved
understanding
molecular
features
bladder
tumors
identification
tumor-associated
antigens
specific
UC,
which
may
serve
druggable
targets.
Despite
notable
advances
clinical
success
ADCs
other
malignancies,
their
full
potential
remains
largely
unmet.
Early
enfortumab
vedotin
sacituzumab
govitecan
demonstrated
antitumor
activity;
however,
multiple
challenges
these
ADCs,
including
on-target,
off-tumor
toxicity
difficulty
maintaining
sustained
responses.
Newer-generation
ADC
constructs,
either
alone
or
approaches,
currently
under
investigation.
This
review
examines
historical
development,
current
landscape,
trends
highlighting
both
progress
made
obstacles
that
continue
hinder
optimal
outcomes.
Journal of Nuclear Medicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. jnumed.124.269024 - jnumed.124.269024
Published: Feb. 13, 2025
Nectin
cell
adhesion
molecule
4
(Nectin-4)
is
an
emerging
biomarker
for
cancer
diagnosis
and
therapy.
We
developed
a
Nectin-4-targeted
68Ga-DOTA-Sar10-Nectin-4
(68Ga-FZ-NR-1)
PET/CT
radiotracer
detecting
Nectin-4
expression
in
tumor
model
triple-negative
breast
(TNBC)
patients.
Methods:
A
series
of
radiotracers-68Ga-FZ-NR-1,
68Ga-DOTA-polyethylene
glycol
5-Nectin-4
(68Ga-FZ-NR-2),
10-Nectin-4
(68Ga-FZ-NR-3)-were
synthesized,
their
targeting
ability
specificity
were
evaluated
vitro
vivo.
In
experiments
performed
the
MDA-MB-468
(Nectin-4-positive)
MDA-MB-231
(Nectin-4-negative)
lines.
imaging
models
was
to
assess
Nectin-4-targeting
radiotracers.
After
preclinical
screening,
68Ga-FZ-NR-1
selected
safety
efficacy
evaluation
first-in-human
trial
TNBC
Positive
lesions
biopsied
analyzed
by
immunohistochemistry
determine
levels.
Results:
The
3
68Ga-labeled
radiotracers
exhibited
high
radiochemical
purity,
stability,
strong
affinity
Nectin-4.
uptake
studies
showed
that
effectively
targeted
cells,
highest
efficacy.
model,
taken
up
at
higher
rates
than
68Ga-FZ-NR-2
68Ga-FZ-NR-3,
it
favorable
pharmacokinetics
profiles.
thus
subsequent
clinical
trials.
identified
tumors
9
patients
with
TNBC,
which
confirmed
18F-FDG
PET/CT.
Biopsy
samples
revealed
positive
corresponded
areas
expression.
Conclusion:
(68Ga-FZ-NR-1,
68Ga-FZ-NR-2,
68Ga-FZ-NR-3)
evaluated.
Preclinical
demonstrated
can
identify
preliminary
study,
used
visualize
Nectin-4-expressing
immunohistochemistry.
This
provides
noninvasive
approach
assessment
potential
basis
development
treatments
TNBC.
European Journal of Cancer,
Journal Year:
2025,
Volume and Issue:
unknown, P. 115427 - 115427
Published: April 1, 2025
The
antibody-drug
conjugate
enfortumab
vedotin
(EV)
received
approval
in
patients
with
metastatic
urothelial
carcinoma
(mUC).
EV-related
cutaneous
toxicities
are
frequently
reported,
whether
AEs
association
survival
may
exist
is
still
unknown.
We
aim
to
report
the
between
and
receiving
EV.
This
retrospective
study
enrolled
treated
monotherapy
EV
from
two
oncology
centers,
followed
up
for
at
least
3-months,
data
collection
demographics,
treatments,
toxicities,
outcomes.
primary
endpoint
was
progression-free
(PFS)
experiencing
or
not.
Overall
(OS)
secondary
endpoint.
Data
63
July
19,
2019,
March
12,
2024,
were
collected.
Among
them,
18
(28.6
%)
any-grade
during
treatment
showed
significantly
longer
median
PFS
(mPFS:
9.2
vs.
4.7
months,
hazard
ratio
[HR]
0.35;
p
=
0.0041)
OS
(mOS:
not
reached
8.4
HR
0.38;
0.0253).
multivariate
analysis
a
significant
of
improved
(HR
0.40,
0.0319),
did
demonstrate
even
if
tendency
kept
0.41,
0.067).
These
results
support
that
toxicity
(skin
rash)
had
prolonged
PFS.
With
recent
expansion
combined
using
plus
pembrolizumab
first-line
mUC
patients,
need
be
carefully
monitored
optimized
dedicated
management
provided,
considering
predictive
patient
outcome.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(5), P. 296 - 296
Published: April 23, 2025
Nectin-2
and
Nectin-4
are
cell
adhesion
molecules
associated
with
the
progression
of
various
cancers.
The
main
goal
this
pilot
study
was
to
evaluate
expression
patterns
in
laryngeal
squamous
carcinoma
(LSCC).
A
retrospective
conducted
on
tissue
microarray
(TMA)
samples
derived
from
31
patients
who
underwent
total
laryngectomy.
findings
revealed
heterogenous
both
tumor
cells
surrounding
stroma,
being
significantly
higher
than
expression.
Specifically,
74%
cases
showed
weak
cytoplasmic
staining
for
Nectin-2,
while
41.93%
exhibited
strong
Nectin-4.
Both
expressions
were
more
pronounced
at
invasive
margins.
Although
no
significant
differences
observed
across
grades
(W
=
83.500;
z
−0.463;
p
0.658),
noted.
Well-differentiated
tumors
(Grade
1),
80.65%
cases,
predominantly
membranous
staining,
including
epithelial
mucosal
surface.
Conversely,
less-differentiated
2
3),
a
shift
toward
evident.
74.19%
Grade
100%
3
predominant
localization
This
transition
also
evident
normal
superficial
epithelium
malignant
tissue.
These
observations
suggest
that
alterations
subcellular
may
be
carcinogenesis
could
serve
as
potential
markers
assessment
precancerous
lesions
aggressiveness
tumors.
Measles
virus
(_Morbillivirus_
abbreviated
as
MV,
but
more
recently
MeV)
is
the
causal
agent
of
disease,
thought
to
have
existed
at
least
4000
years
ago,
affecting
predominantly
infants,
also
immunocompromised
individuals
and
others
remaining
a
public
health
issue
today
globally.
In
this
review,
we
are
discussing
historical
background
about
MeV
infection
modern–day
research,
then
delving
into
disease
what
known
immunisation
against
disease.
We
elucidate
viral
structure
function
proteins.
The
genomic
stability
particle
suggestive
that
third
pathogen
with
potential
be
eradicated
(after
Variola
Rinderpest
viruses)
requires
further
biological
immunological
clarification.
Here
therefore
covers
bow
from
mechanism
clinical
aspects
touching
topics
like
cellular
receptor–associated
factors
immunology
infection.
highlight
actual
knowledge
innate
immune
response
during
infection,
including
chemokine
cytokine
expression
finalised
by
current
understanding
adaptive
responses
MeV.
